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ABSTRACT
Despite reductions in mortality from the use of highly active antiretroviral therapy
(HAART), the presence of latent or transcriptionally silent proviruses prevents HIV
cure/eradication. We have previously reported that DNA-dependent protein kinase
(DNA-PK) facilitates HIV transcription by interacting with the RNA polymerase II
(RNAP II) complex recruited at HIV LTR. In this study, using different cell lines and
peripheral blood mononuclear cells (PBMCs) of HIV-infected patients, we found that
DNA-PK stimulates HIV transcription at several stages, including initiation, pauserelease and elongation. We are reporting for the first time that DNA-PK increases
phosphorylation of RNAP II C-terminal domain (CTD) at serine 5 (Ser5) and serine
2 (Ser2) by directly catalyzing phosphorylation and by augmenting the recruitment
of the positive transcription elongation factor (P-TEFb) at HIV LTR. Our findings
suggest that DNA-PK expedites the establishment of euchromatin structure at HIV
LTR. DNA-PK inhibition/knockdown leads to the severe impairment of HIV replication
and reactivation of latent HIV provirus. DNA-PK promotes the recruitment of Tripartite
motif-containing 28 (TRIM28) at LTR and assists the release of paused RNAP II
through TRIM28 phosphorylation. These results provide the mechanisms through
which DNA-PK controls the HIV gene expression and, likely, can be extended to
cellular gene expression, including during cell malignancy, where the role of DNA-PK
has been well-established.

INTRODUCTION

oftentimes with a single daily dose. However, even
after several years of undetectable viremia, the virus
resurrects out of latent reservoirs and quickly re-emerges
in circulation if HAART is interrupted [1, 2]. Thus, the
presence of latent or transcriptionally silent HIV provirus
is a major hurdle to HIV eradication. The persistence of

Combination anti-retroviral therapy (cART),
commonly known as highly active antiretroviral
therapy (HAART), is able to suppress replication of
human immunodeficiency virus (HIV) quite effectively,
www.oncotarget.com
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HIV in patients, despite prolonged treatment, has renewed
interest in understanding the molecular mechanisms that
control HIV life cycle. It is well accepted that the state
of HIV transcription dictates the prevalence of either
productively replicating or latent HIV proviruses in the
cells [3–8]. The bigger pool of latent proviruses consists
of defective HIV progeny, which are incompetent in
generating fully functional HIV [9, 10]. However,
defective proviruses can still transcribe their genes and
produce some of the viral proteins that contribute to
HIV-mediated cytotoxicity [11]. Therefore, thorough
understanding of the mechanisms that regulate HIV
transcription is a prerequisite for effectively applying any
strategy for HIV eradication or a functional cure.
Analogous to host gene transcription, HIV
transcription is regulated by the well-controlled
phosphorylation events of the carboxyl-terminal domain
(CTD) of the largest subunit of the RNA polymerase II
(RNAP II) [12]. The mammalian RNAP II CTD consists
of 52 tandem repeats of a consensus sequence Tyr1Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 [13, 14]. More than
half a dozen kinases are known to phosphorylate CTD
of RNAP II. Among these, the importance of cyclindependent kinases (mainly CDK7 for phosphorylation
of Serine 5 (Ser5), and CDK9 for phosphorylation of
Serine 2 (Ser2)) during HIV transcription has already
been established [12, 13, 15]. We recently discovered
that the DNA-dependent protein kinase (DNA-PK) is
another kinase that phosphorylates the CTD of RNAP
II and plays an important role during HIV transcription.
Previously, we had documented the parallel presence of
DNA-PK along with RNAP II throughout the HIV proviral
genome during HIV transcription [16]. By performing in
vitro kinase assays, we showed that DNA-PK is able to
phosphorylate all three serine residues (Ser2, Ser5, and
Ser7) of the CTD region of RNAP II. We found that
the transactivator of transcription (Tat) protein, which
is vital for HIV transcription, is a potential substrate of
DNA-PK. The finding that cellular activation enhances
nuclear translocation of DNA-PK and its activation further
supports our observation of greater DNA-PK recruitment
at HIV long terminal repeat (LTR) following cellular
activation [16, 17].
The human DNA-PK is a nuclear kinase that
specifically requires association with DNA for its
activity [18–21]. DNA-PK holoenzyme consists of two
components: a 450 kDa catalytic subunit (DNA-PKcs)
[22], which is a serine/threonine kinase, and a regulatory
component known as Ku [23]. Ku is a heterodimer
comprised of two subunits, one 70 kDa [24] and another
80 kDa [25]. The 70 kDa subunit possesses ATPase and
DNA helicase activities. The vital role of DNA-PK in
the non-homologous end joining (NHEJ) DNA-repair
pathway is well-recognized [26, 27].
HIV transcription pauses after transcribing around
first 60 bp [28, 29]. RNAP II pausing is mainly attributed
www.oncotarget.com

to the binding of negative elongation factor (NELF) and
DRB sensitivity-inducing factor (DSIF) to HIV LTR
[28, 30]. Later, the Tat protein, by recruiting positive
transcription elongation factor b (P-TEFb), relieves
RNAP II pausing [31, 32]. The CDK9 subunit of P-TEFb
phosphorylates the NELF and DSIF subunits, which either
converts them to a positive elongation factor or removes
them from LTR [3]. Transcriptional elongation needs the
sequential specific phosphorylation events at RNAP II
CTD in order to transform RNAP II to an elongating or
processive enzyme.
Phosphorylation of Ser5 residue of the RNAP
II CTD is linked to the initiation phase of transcription
[33, 34], whereas phosphorylation of Ser2 is found to
be correlated with the elongation phase of transcription,
also during HIV gene expression [28, 35, 36]. In addition
to DSIF and NELF, another factor, the tripartite motifcontaining 28 (known as TRIM28, KAP1, TIF1β),
has been shown recently to support RNAP II pausing
at certain cellular genes [37–39]. Similar to the SPT5
subunit of DSIF [40], the phosphorylation of TRIM28
converts it from a pausing or negative elongation factor
to a positive elongation factor [39, 41]. DNA-PK is the
principal kinase which directly interacts with TRIM28
and catalyzes the phosphorylation of TRIM28 at serine
824 residue converting it to an elongation factor [39].
Pertaining HIV transcription, the role of TRIM28 is still
not clear. However, the presence of TRIM28 bound with
7SK snRNP complex at HIV LTR has been documented
[42], and the role of TRIM28 during HIV latency has
also been proposed [43]. In addition to ours [16], other
studies have also noted the interaction between RNAP II
and DNA-PK [44]. Moreover, we have shown that DNAPK is a component of RNAP II holoenzyme, recruited
at HIV LTR, and it rides along RNAP II throughout the
HIV genome [16]. Recently, the interaction of TRIM28
with RNAP II and the continuous presence of TRIM28
with RNAP II along cellular genes’ body have been
documented [38, 39]. In our investigation, by attenuating
the activity or cellular levels of DNA-PK, we have
established the role of DNA-PK not only in activating
TRIM28 through phosphorylation, but also in recruiting
TRIM28 and phosphorylated TRIM28 (p-TRIM28, S824)
at HIV LTR.
Several studies focusing on cancer therapy have
targeted DNA-PK with small molecule inhibitors [45–47]
in efforts to kill cancerous cells through accumulation of
unrepaired DNA breaks induced by ionizing radiation
[48, 49]. For this purpose, several DNA-PK inhibitors
have been developed. Early inhibitors, which include
1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone (known
as IC86621), suppressed DNA-PK activity by reversibly
inhibiting its ATP binding. IC86621 was proved to be a
clinically effective DNA-PK inhibitor [50]. Subsequently,
a more specific, class of DNA-PK inhibitors, including
LY294002, was developed that binds selectively to the
700
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kinase domain of DNA-PK [51]. Later, LY294002 became
the template for the development of even more specific
DNA-PK inhibitors, such as NU7026 (2-(morpholin-4-yl)benzo-H-chromen-4-one) which was shown to be 50-fold
more specific for DNA-PK than other kinases [52, 53].
One more related compound, NU7441 (2-N-(morpholino8-benzothiophenyl)-chromen-4-one), was found to be
even more selective for DNA-PK than NU7026 [45, 54–
56]. These highly specific, non-toxic competitive DNAPK inhibitors induce phenotype similar to that of DNA-PK
deficient cell line and DNA-PK knockout mice [45, 56].
The use of these inhibitors severely restricts DNA doublestrand break (DSB) repair, a primary activity of DNA-PK,
and enhances the cytotoxicity of physical and chemical
agents that induce DSB formation, such as ionizing
radiation. Consequently, these inhibitors are being utilized
as anti-cancer agents in several preclinical and phase-I
clinical studies [45, 56–59].
In a prior publication, we suggested an important role
of DNA-PK during HIV transcription, and documented
the continuous presence and gliding of DNA-PK with
RNAP II along the HIV genome during transcription [16].
In the current study, we sought to evaluate the mechanism
through which DNA-PK promotes HIV transcription,
replication, and latent proviral reactivation. We explored
the impact on HIV gene expression after inhibition or
depletion of endogenous DNA-PK, by treating cells with
either specific inhibitors or specific shRNA, respectively.
We assessed the impact of DNA-PK on the phosphorylation
state of RNAP II CTD and on the regulation of epigenetic
changes at HIV LTR. The results were confirmed in various
cell types belonging to different lineages, including the
physiologically relevant primary T cells and cells from HIVinfected patients. We found that DNA-PK plays a major role
during HIV transcription by supporting it at multiple steps.
Consequently, DNA-PK inhibition or removal drastically
impairs HIV transcription, replication, and reactivation
of latent provirus. In latently infected cells, where HIV
provirus is transcriptionally silent, we noted highly reduced
nuclear levels of DNA-PK. We have shown that DNA-PK
promotes the HIV transcriptional initiation by catalyzing
the phosphorylation of RNAP II CTD at Ser5; it relieves
the pausing of RNAP II by catalyzing the phosphorylation
of TRIM28 at S824. Finally, DNA-PK increases the
elongation phase of HIV transcription by augmenting CTD
phosphorylation at Ser2, both by directly catalyzing the
reaction and by co-recruiting P-TEFb at HIV LTR.

those findings and in our quest to define the molecular
mechanisms involved, we evaluated the role of DNAPK in supporting proviral reactivation from latency. Our
hypothesis was that DNA-PK inhibition should impair
HIV transcription, and consequently latent proviral
reactivation. For testing this hypothesis, we assessed the
reactivation of proviruses in latently infected cell lines and
primary T cells in the presence of highly specific and wellestablished DNA-PK inhibitors. Using our established
methodologies, we generated the latently infected THP1, a human myeloid/monocytic cell line, Jurkat, a human
lymphoid/T cell line, and primary CD4+ T cells [8, 60].
Using luciferase assays, we evaluated the impact of DNAPK inhibitors on the reactivation of integrated latent HIV
provirus (pHR’P-Luc) expressing luciferase reporter
gene under the control of the HIV LTR promoter (Figure
1A). The cells were incubated overnight with various
concentrations of different DNA-PK inhibitors or DMSO,
as solvent control. The cells were stimulated with either
Tumor Necrosis Factor alpha (TNF-α) or T cell receptor
(TCR). A clear dose-dependent inhibition of HIV proviral
reactivation by DNA-PK inhibitors was observed in all
cell types, indicated by the reduced luciferase counts in
cells treated with the inhibitors compared to the control
(Figure 1B–1D). The more specific DNA-PK inhibitors,
NU7441 and NU7026, demonstrated better effect in
restricting HIV gene expression than the less specific
inhibitor IC86621. Since IC86621 was comparatively less
efficient in restricting HIV transcription, in successive
experiments we primarily used NU7441 and NU7026.
In order to exclude the possibility that the loss of
luciferase activity was due to non-specific cell cytotoxicity
of DNA-PK inhibitors, we treated the cells with NU7441
and NU7026 and then assessed cell viability using
the MTS assay. We did not find any significant cell
cytotoxicity in Jurkat and THP-1 cells up to 64 µM even
after 5 days of culture (Figure 1E and 1F). However, in
case of primary CD4+ T cells, DNA-PK inhibitors showed
some toxicity at concentrations around 32 µM (Figure 1G).
Therefore, in our successive analyses involving primary T
cells, we used concentrations of inhibitors below 32 µM.
Taken together, our data suggest that DNA-PK
inhibitors efficiently restrict proviral reactivation from
latency by down-regulating HIV gene expression. The
stronger suppression of HIV gene expression by the more
specific DNA-PK inhibitors indicates target-specific
inhibition and confirms the vital role of DNA-PK during
HIV transcription.
We further used U1 (Figure 2A) and J1.1 (Figure
2B) cells to investigate the effect of DNA-PK inhibitors
on latent proviral reactivation and HIV replication. The
U1 is a latently infected monocytic cell line, while the
J1.1 is a latently infected Jurkat T cell line; both carry
an integrated replication-competent latent HIV provirus.
The cells were treated with different amounts of DNAPK inhibitors or DMSO control, overnight (~11 hours).

RESULTS
DNA-PK inhibitors are strong repressors of HIV
transcription, replication, and reactivation of
latent HIV provirus
We have shown previously that DNA-PK plays a
significant role during HIV transcription [16]. To extend
www.oncotarget.com
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Figure 1: DNA-PK inhibitors repress HIV transcription without showing cytotoxicity. (A) HIV- based lentiviral vector,

pHR’P-Luc, which express luciferase reporter gene through HIV LTR promoter. (B) THP-1, a monocytic cell line, (C) Jurkat, a T cell line,
and (D) primary CD4+ T cells carrying integrated latent pHR’P-Luc provirus in their genome were treated with indicated amounts of the
DNA-PK inhibitors NU7441, NU7026, IC86621 or DMSO solvent-control along with or without 10 ng/ml of TNF-α. After 48 hours cells
were lysed, and equal amount of proteins were used for luciferase assays. MTS cell viability assays were also performed after 5 days of
culture (E) THP-1-pHR’P-Luc, (F) Jurkat-pHR’P-Luc and (G) primary CD4+ T cells-pHR’P-Luc. The results represent the Mean ± SD of
three independent assays. The p value of statistical significance was set at either: p < 0.05 (*), 0.01 (**), 0.001 (***), or 0.0001 (****) when
compared with DMSO treated stimulation as control.
www.oncotarget.com
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Figure 2: DNA-PK inhibitors drastically impair latent proviral reactivation and HIV replication. For assessing the impact

of DNA-PK inhibitors on the latent proviral reactivation and replication, the cells were pre-incubated with indicated amounts of DNAPK inhibitors or DMSO control, overnight. Next day, cells were supplied with fresh media containing inhibitors and/or 10 ng/ml TNF-α,
accordingly, and further incubated for 48 hours. The cell supernatants were collected and used for the Reverse Transcriptase (RT) assays
performed in (A) U1 (latently infected U937 based monocytic cell line), (B) J1.1 cell line (latently infected Jurkat based T cell line) and (C)
Freshly infected primary CD4+ T cells. The results represent the mean ± SD of three independent assays. The statistical significance was set
at: p < 0.05 (*), 0.01 (**), 0.001 (***), or 0.0001 (****) versus DMSO treated stimulated cells, as control.
www.oncotarget.com
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Next day, cells were supplied with fresh media containing
inhibitors and/or 10 ng/ml TNF-α for another 48 hours,
and the activity of HIV reverse transcriptase (RT) was
analyzed in cell supernatants. We noticed a steady
suppression of HIV replication by DNA-PK inhibitors in
a dose-dependent manner (Figure 2A and 2B). Similar to
the results obtained in the transcription assays, the more
specific inhibitors NU7441 and NU7026 were more
effective than IC86621 in restricting HIV replication in
both cell types. Comparable results from both J1.1 and U1
cells confirmed the vital role of DNA-PK in facilitating
HIV gene expression and replication irrespective of cell
lineage. These data also suggest the therapeutic potential
of DNA-PK inhibitors in restricting the reactivation of
latent HIV proviruses and subsequent replication.
To provide physiological relevance to the anti-HIV
effect of DNA-PK inhibitors, we examined the impact of
DNA-PK inhibitors on HIV replication in primary CD4+ T
cells isolated from human peripheral blood mononuclear
cells (PBMCs) (Figure 2C). CD4+ T cells were activated
with PHA and IL-2, infected with a CXCR4 tropic HIV
virus (NL4-3), and treated with different concentrations
of the most effective DNA-PK inhibitor, NU7441.
The culture medium containing NU7441 was replaced
every 3 days. The results of the RT assays performed
at 5, 7, and 9 days post-infection showed that NU7441
effectively repressed HIV replication in primary CD4+
T cells in a dose-dependent fashion. Taken together, our
results confirm the pivotal role of DNA-PK during HIV
transcription, latent proviral reactivation and replication.

3A and 3B) and U937 cells (Figure 3C and 3D) was
observed significantly (Figure 3). However, total RNAP II
levels were not much affected. These results were further
validated in different cell lines: THP-1 (a myeloid cell
line); MT-4 (a T cell line harboring HTLV in its genome);
2D10 (a Jurkat cell line carrying latent HIV in its genome)
[8, 61]; and primary cells (Supplementary Figures 1–4).
The parallel impairment of HIV gene expression (Figures
1 and 2) and CTD phosphorylation (Figure 3), upon DNAPK inhibition, suggests an important role for DNA-PKmediated CTD phosphorylation in generating processive
RNAP II, a requirement for efficient gene expression.
In addition, the present study validates our prior in vitro
findings and confirms that RNAP II CTD is indeed the
physiologic substrate for DNA-PK. The impact of DNAPK inhibitors on both types of CTD phosphorylation
modifications indicates that DNA-PK plays a role in
both the initiation and elongation phases of transcription.
Notably, the reduction in Ser5 phosphorylation is less
pronounced than the reduction in Ser2 phosphorylation
following inhibition of DNA-PK, indicating that DNA-PK
facilitates HIV transcription predominantly by supporting
the elongation phase.
Overall, these results confirm that DNA-PK
catalyzes the phosphorylation of RNAP II CTD and
suggest that the observed reduction in HIV transcription
and replication following treatment with DNA-PK
inhibitors is a direct consequence of reduced CTD
phosphorylation of RNAP II.

Knockdown of endogenous DNA-PK restricts
RNAP II CTD phosphorylation

DNA-PK promotes HIV transcription by
enhancing the phosphorylation of C-terminal
domain (CTD) of RNA polymerase II (RNAP II)

In order to confirm that the effects we observed
after DNA-PK inhibition were due to the impairment
of DNA-PK activity, we performed a knockdown of
endogenous DNA-PK. To knockdown endogenous DNAPK, the U937 and Jurkat cells were infected with lentiviral
vectors expressing shRNAs either against the catalytic
subunit of DNA-PK (DNA-PKc) or scrambled shRNA, as
control. The neutrality of scrambled shRNA towards HIV
and cellular genomes was confirmed by using the NCBI
program Blast [8]. Depending on the degree of DNA-PK
knockdown in different clones, we selected one clone each
for U937 (clone U3) (Figure 4A and 4B) and Jurkat (clone
J3) (Figure 4C and 4D) for further analysis. In the case
of the U937 clone U3, we were able to obtain more than
85% knockdown (Figure 4A), whereas in the case of the
Jurkat clone J3, the knockdown was 70% (Figure 4C).
We also noted profound cell death in Jurkat cells, with
over 70% depletion of endogenous DNA-PK. In both
knockdown clones, we noted significant loss of the CTD
phosphorylation, at both Ser2 and Ser5 (Figure 4). We also
observed some reduction of the total RNAP II levels in
U937 cells, likely due to high level of DNA-PK depletion.
Given the fact that RNAP II is also required for RNAP

In our prior publication, by performing in vitro
kinase assays, we have shown the phosphorylation of
RNAP II CTD by DNA-PK, a crucial post-translational
modification, is required to generate complete functional
transcripts, as it makes RNAP II processive [16]. In
order to understand whether the observed inhibition of
the HIV gene expression by DNA-PK inhibitors is the
result of insufficient phosphorylation of RNAP II CTD,
we assessed the impact of DNA-PK inhibitors on RNAP
II CTD phosphorylation. Jurkat (Figure 3A) and U937
(Figure 3C) were treated with the DNA-PK inhibitor
NU7441 at different concentrations for 3 hours. The
nuclear extracts were run on an acrylamide gel, transferred
to a nitrocellulose membrane, and the membrane was
developed using antibodies that recognize specific epitopes
present on the CTD of phosphorylated RNAP II. The H5
antibody recognizes the RNAP II with CTDs carrying
Ser2 phosphorylation, while the H14 antibody recognizes
epitopes of CTD carrying Ser5 phosphorylation. A dosedependent effect of NU7441 on the phosphorylation of
Ser2 and Ser5 of RNAP II CTD in both Jurkat (Figure
www.oncotarget.com
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Figure 3: DNA-PK inhibitors repress HIV transcription by restricting RNAP II CTD phosphorylation. (A) Jurkat cells
and (C) U937 cells were treated with increasing concentrations of the DNA-PK inhibitor NU7441 and then activated with TNF-α (10 ng/
ml) for 3 hours. The cells were harvested, and nuclear extracts were assessed through western blot. The phosphorylation state of carboxyl
terminal domain (CTD) of RNA polymerase II (RNAP II) was assessed through western blot using antibodies that are specific for RNAP II
and its phosphorylated forms (Ser2 and Ser5). HDAC1 was used as loading control. The presented data is one representative western blot
analysis out of three. Densitometric analyses were performed on western blot bands using ImageJ software for both (B) Jurkat cells and (D)
U937 cells. The results represent the Mean ± SD of three different independent assays. Statistical significance is set as p < 0.05 (*), 0.01 (**),
or 0.001 (***) compared to stimulated, but without DNA-PK inhibitor.
www.oncotarget.com
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Figure 4: Knockdown of DNA-PK restricts RNAP II CTD phosphorylation. The endogenous DNA-PK was knocked down

using lentiviral vectors expressing shRNA sequences specific for DNA-PK. The vector expressing non-targeting scrambled shRNA
sequence was used as control. Western blot assays showing nuclear levels of DNA-PK, total RNAP II, RNAP II (Ser2) and RNAP II (Ser5)
in (A) U937 cells and corresponding DNA-PK knockdown clone U3 and (C) Jurkat cells and DNA-PK knockdown clone J3. β-Actin and
HDAC1 were used as loading controls. Densitometric analyses were performed on (B) U937 cells and (D) Jurkat cells western blot’s bands
using imageJ software. Error bars represent the SD of three separate experiments. Statistical significance was set as p < 0.05 (*), 0.01 (**),
0.001 (***) or 0.0001 (****) versus scrambled shRNA control.
www.oncotarget.com
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II gene expression, severe defects to the functionality of
cellular RNAP II hamper its own expression, an effect also
observed upon using strong inhibitors of P-TEFb (data not
shown). These results, along with those obtained using
DNA-PK inhibitors (Figure 3), confirm that DNA-PK
catalyzes RNAP II CTD phosphorylation, which promotes
HIV transcription.

level of DNA-PK in latently infected cells, HIV provirus
was unable to initiate its transcription. However, upon
induction with TNF-α, the latent provirus gets reactivated,
as indicated by the rapid, more than 3-fold enrichment
of RNAP II at the promoter. Parallel to the RNAP II
accumulation, we found enhanced recruitment of DNAPK at the promoter, validating the pivotal role of DNAPK in HIV transcription. The enhanced nuclear-levels of
DNA-PK upon cell stimulation were also validated in
other experiments (Figures 3 and 8). As anticipated, we
noted relatively less recruitment of P-TEFb subunits at
the promoter region. However, at a distal Nuc-2 region
of LTR, we noticed significantly higher enrichment of
P-TEFb upon activation, validating the main role of
P-TEFb during the elongation phase of transcription.
On the other hand, after activation, CDK7 was enriched
as expected at the LTR promoter but not at the Nuc-2
region, again validating its requirement especially during
the initiation phase of HIV transcription. As shown in our
previous publication [16], we noted better enrichment
of DNA-PK at the downstream Nuc-2 region of LTR
after activation, validating the main role of DNA-PK
during transcriptional elongation. However, in DNA-PK
deficient cells, we observed highly reduced recruitment
of almost all of the factors, further validating the highly
restricted ongoing HIV transcription. Interestingly, even
after stimulation with TNF-α, we found highly impaired
enrichment of P-TEFb at LTR, confirming a clear role of
DNA-PK in P-TEFb recruitment. Notably, we observed
a relatively smaller impact of DNA-PK knockdown on
CDK7 recruitment at the promoter region, suggesting
that CDK7 recruitment at LTR does not depend on the
DNA-PK.
Together, our results demonstrated that DNAPK promotes HIV transcription, not only by directly
catalyzing the phosphorylation of CTD of RNAP II [16],
but also by enhancing the recruitment of P-TEFb at HIV
LTR, which further increases CTD phosphorylation.

DNA-PK promotes HIV transcription by
supporting the recruitment of P-TEFb at HIV LTR
The interaction between DNA-PK and P-TEFb
has been previously documented [62, 63]. CDK9
subunit of P-TEFb is the major kinase that catalyzes
the phosphorylation of RNAP II CTD. This observation
suggests that in addition to directly catalyzing the
phosphorylation of CTD of RNAP II, DNA-PK may
also enhance CTD phosphorylation by increasing the
recruitment of P-TEFb at HIV LTR. Therefore, we
examined the recruitment profile of the main subunits of
P-TEFb, Cyclin T1, and CDK9, at HIV LTR by performing
chromatin immunoprecipitation (ChIP) assays in wildtype and DNA-PK knockdown cells. Given that T cells
are the main reservoirs of latent proviruses, we performed
experiments using Jurkat T cells. The recruitment kinetics
of P-TEFb were analyzed in knockdown (J3) and control
Jurkat clones harboring latent HIV provirus, pHR’-PNLwildTat-d2GFP (Jurkat-HIV-GFP) (Figure 5A), before and
after activation with TNF-α (10 ng/ml) for 30 minutes.
The ChIP assays were performed using antibodies
against Cyclin T1 and CDK9. We also analyzed CDK7,
a component of the TFIIH transcription factor, which
catalyzes the phosphorylation of RNAP II CTD primarily
at Ser5 residue, hence playing vital role during the
initiation phase of HIV transcription [35]. As control,
we assessed the recruitment of RNAP II, a marker of
ongoing transcription, and an auto-phosphorylated form
of DNA-PK, specifically at S2056, p-DNA-PK (S2056),
which marks the functionally active form of DNA-PK.
The immunoprecipitated DNA was examined by using
two primer sets: one amplifying the promoter region of
the LTR (–116 to +4 with respect to the transcription
start site), which provides a measure of the factors
involved in transcriptional initiation (Figure 5B), and
the other amplifying the downstream nucleosome-2
region (Nuc-2) of the LTR (+286 to +390 with respect to
the transcription start site), which quantifies the factors
involved in the elongation phase of HIV transcription
(Figure 5C). The IgG control was subtracted from all
samples as background. The results were normalized
with the housekeeping GAPDH gene (–145 to +21), a
constitutively expressing cellular gene. In Figure 5B,
the low level of RNAP II at the promoter region of
latent provirus marks reduced ongoing transcription.
Interestingly, we also noted highly reduced presence
of p-DNA-PK (S2056), suggesting that due to reduced
www.oncotarget.com

DNA-PK depletion in cells severely impairs HIV
gene expression
To confirm the direct involvement of DNA-PK
in promoting HIV transcription, we assessed the effect
of DNA-PK knockdown on HIV gene expression. We
superinfected DNA-PK knockdown cells or control cells
that carry scrambled shRNA, with pHR’-PNL-H13LTatd2GFP or pHR’-PNL-wildTat-d2GFP. These nonreplicating HIV have similar backbones, and both express
the GFP reporter gene under the control of the HIV LTR
promoter (Figure 5A). The only difference between them
is that one expresses wild-type Tat and the other mutated
Tat (H13L), a partially defective Tat mutant highly
prevalent in latent proviruses [8, 61, 64]. Interestingly,
for both Jurkat and U937 cells, upon superinfection with
pHR’-PNL-H13LTat-d2GFP in DNA-PK depleted cells,
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Figure 5: DNA-PK facilitates the recruitment of P-TEFb at HIV LTR. (A) Schematic diagram of HIV based lentiviral vector,

which carry either mutated Tat (H13L) or wild-type Tat and express GFP as reporter. In these experiments VSV-G pseudotyped HIV,
harboring wild-type Tat gene (HIV-GFP), was used. The DNA-PK knockdown (J3) or control Jurkat cells with scrambled shRNA were
infected with HIV-GFP and the provirus was allowed to become latent. The ChIP assays were performed before and after reactivating
the latent provirus with TNF-α (10 ng/ml) for 30 minutes. ChIP assays were done using indicated antibodies and two transcriptionally
relevant regions of LTR were amplified using specific primer sets: (B) promoter region of the LTR; and (C) Nuc-2 region of the LTR. HIV
DNA levels were calculated as percentages of the reaction input after background subtraction. Error bars represent the mean ± SD of four
independent experiments and three separate real-time qPCR measurements. Statistical significance, p < 0.05 (*), 0.01 (**), or 0.001 (***),
indicates enrichment at LTR following latent proviral reactivation, in both wild and DNA-PK knockdown conditions.
www.oncotarget.com
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we noted more than 4-fold reduction of GFP positive cells
in comparison to control cells carrying scrambled shRNA
(Figure 6A and 6B). However, in cells infected with
HIV expressing wild-type Tat gene, pHR’-PNL-wildTatd2GFP, we observed relatively less impaired HIV gene
expression, but still more than 2-fold reduction of GFP
positive cells in DNA-PK depleted cells. Given the fact
that the expression of GFP gene is controlled by the HIV
LTR promoter in these HIV constructs, the GFP expression
marks HIV gene expression and LTR activation. These
results demonstrate that DNA-PK plays a crucial role in
promoting HIV gene expression. Accordingly, similar
to GFP expression, we noticed reduced levels of Tat in
DNA-PK knockdown U2 and U3 clones infected with
pHR’-PNL-wildTat-d2GFP (Figure 6C), suggesting that
a DNA-PK-mediated transcriptional boost is essential for
generating optimal Tat levels as well.
The results were also confirmed at the mRNA
level. The cellular RNAs were extracted from control and
DNA-PK knockdown cell clones infected with pHR’PNL-wildTat-d2GFP; cDNAs were synthesized and equal
amounts of cDNAs were quantified via real-time PCR
analysis (qPCR) using primer set for the downstream
Nuc-2 region of HIV LTR. Analogously to GFP levels,
we observed a significantly reduced expression of HIV
mRNA in DNA-PK knockdown clones compared to cells
that express normal levels of DNA-PK (Figure 6D and
6E). These data confirm that GFP expression is impaired
at transcriptional level in DNA-PK deficient cells.

absence or presence of the DNA-PK inhibitor (Figure 7A
and 7B). The immunoprecipitated DNA was analyzed
using two different primer sets. One primer set amplified
the promoter region of the LTR (–116 to +4 with respect
to the transcription start site) (Figure 7A) and the other
the nucleosome-1 (Nuc-1) region of the LTR (+30 to
+134 with respect to the transcription start site) (Figure
7B), an adjacent critical region, where slight epigenetic
changes affect overall HIV gene expression [66, 67]. The
data obtained through immunoprecipitation using control
IgG was subtracted from all samples as background and
results were normalized with housekeeping GAPDH gene
expression (–145 to +21) level. At both promoter and Nuc-1
regions, the latent proviruses had low levels of associated
RNAP II (Figure 7), which increased by several folds
following TNF-α treatment. However, in the presence of
the DNA-PK inhibitor, TNF-α stimulation was significantly
weak. The limited amount of RNAP II at HIV LTR in the
presence of DNA-PK inhibitors is an indication of impaired
HIV transcription. In parallel, we noted reduced recruitment
of DNA-PK and P-TEFb (cyclinT1) in NU7441 treated
cells (Figure 7A and 7B). Additionally, since pHR’P-Luc
does not carry Tat gene, our data validate that Tat is not
required for DNA-PK recruitment at LTR.
TNF-α activates (nuclear translocation) NF-κB,
and the greater recruitment of p65, a main subunit of
NF-κB, marks the enhanced NF-κB binding at LTR after
activation. Consistent with the fact that NF-κB binding
sites reside in the promoter area of LTR, we found higher
recruitment of p65 in the promoter area after stimulation
with TNF-α (Figure 7A). Notably, we also observed
some recruitment of p65 in the neighboring Nuc-1 region
after stimulation with TNF-α. Given the ChIP resolution
limit of ~500 bp, an overlap of signals between adjacent
regions, such as promoter and Nuc-1, was expected.
After binding to the promoter, NF-κB is known to recruit
histone acetyltransferases (HATs) at HIV LTR, which
in turn acetylate the core histones [68]. The augmented
levels of acetylated histone H3 (H3-Ac), especially in
the Nuc-1 region, marks the presence of higher levels of
acetylated core histones at HIV LTR. We also observed
the concomitant loss of histone deacetylases, HDACs,
(HDAC3) from LTR further suggests that not only
the recruitment of HATs, but dissociation of HDACs
from LTR is responsible for establishing euchromatin
structures at LTR. Following the treatment with NU7441,
the euchromatic marker H3-Ac went down; instead, the
heterochromatic marker H3K27me3 got established at
HIV LTR (Figure 7). These heterochromatic markers
indicate the presence of transcriptionally repressive
heterochromatin structure at HIV LTR, resulting in
reduced levels of RNAP II and DNA-PK at LTR, which
eventually translate to reduced HIV transcription, gene
expression, and replication.
Consequently, it can be deduced from these
results that DNA-PK enhances HIV gene expression by

DNA-PK enhances HIV transcription by
facilitating the recruitment of transcriptional
machinery and generating transcriptionally
active euchromatin structures at HIV LTR
It is well-established that the type of chromatin
structure and the transcription factors present at the gene
promoter and nearby regions regulate its transcription [60,
65]. We examined the recruitment of the main transcription
factors and induced chromatin structures at and around the
HIV LTR promoter. Heterochromatin or closed chromatin
structures repress transcription, whereas, euchromatin
or open chromatin structures facilitate transcription by
allowing access to the transcription machinery at the
promoter [3, 5, 7]. Hence, to characterize the underlying
molecular mechanisms through which DNA-PK promotes
HIV gene expression and replication, we evaluated the
changes to chromatin structures at HIV LTR before and
after inhibiting DNA-PK.
To examine whether DNA-PK inhibitors instigate the
generation of transcriptionally repressive heterochromatin
structures at HIV LTR, ChIP assays were performed. The
most specific inhibitor of DNA-PK, NU7441 (12 µM), was
used to assess the impact of DNA-PK inhibition in JurkatpHR’P-Luc cell line. ChIP assays were performed before
and after activating the latent provirus with TNF-α in the
www.oncotarget.com
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Figure 6: DNA-PK plays a vital role in HIV gene expression. Flow cytometric analyses of freshly infected DNA-PK knockdown
or control cells with either pHR’-PNL-H13LTat-d2GFP or pHR’-PNL-wildTat-d2GFP. (A) DNA-PK knockdown Jurkat clone J3 and
control Jurkat with scrambled shRNA. (B) DNA-PK knockdown U937 cell clones, U2 and U3, and control cells with scrambled shRNA.
After 48 hours post-infection, GFP positive cells were analyzed using a flow cytometer. The uninfected Jurkat and U937 were used as
background control. (C) Tat protein levels in DNA-PK knockdown U2 and U3 clones infected with pHR’-PNL-wildTat-d2GFP analyzed
via western blot. (D and E), the relative expression levels of HIV mRNA in DNA-PK knockdown and scrambled control cells were
evaluated via RT-qPCR. The qPCR results represent the mean ± SD of three independent assays. Statistical significance, p < 0.001 (***),
marks restriction to HIV gene expression, following DNA-PK knock down.
www.oncotarget.com
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Figure 7: DNA-PK facilitates both the recruitment of transcription factors and establishment of euchromatin structures
at HIV LTR. ChIP analysis in Jurkat-pHR’P-Luc before and after activating latent HIV provirus with TNF-α in the absence or presence of

DNA-PK inhibitor NU7441. The cellular chromatin was immunoprecipitated using indicated antibodies. The recovered DNA was analyzed
using primer sets amplifying (A) the promoter region of the LTR, and (B) nucleosome-1 (Nuc-1) region of the LTR. Data is represented
as percentages of the input nuclear extract after background subtraction. Results represent the mean ± SD of two independent experiments
and three separate real-time qPCR measurements. Statistical analysis signifies the recruitment kinetics following reactivation of the latent
provirus in the presence of NU7441 at HIV LTR; p < 0.05 (*).
www.oncotarget.com
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facilitating the establishment of transcriptionally active
chromatin structures at HIV LTR. DNA-PK inhibitors
restrict HIV transcription by reversing those changes and
inducing the establishment of transcriptionally repressive
heterochromatin structures at LTR.

Figure 9B). In case of wild-type cells with scrambled
shRNA, upon TNF-α treatment the latent provirus got
reactivated, indicated by the higher recruitment of RNAP
II. Interestingly, in parallel to the recruitment profile
of DNA-PK after activation, we observed enhanced
recruitment of TRIM28 at both the promoter and Nuc-2
regions. However, we noticed relatively more enrichment
of p-TRIM28-(S824) at the Nuc-2 region after activation.
In case of DNA-PK knockdown cells, we noticed impaired
recruitment of TRIM28 and p-TRIM28-(S824) at HIV
LTR. However, upon stimulation with TNF-α, we found
some, but still highly restricted recruitment of TRIM28
and p-TRIM28-(S824). The decrease in the recruitment
of TRIM28 and p-TRIM28-(S824) at HIV LTR following
DNA-PK depletion, clearly suggests a contribution of
DNA-PK in TRIM28 recruitment at HIV LTR. Moreover,
restricted RNAP II levels at both promoter and Nuc2 region of provirus in DNA-PK knockdown cells,
further validates the highly reduced ongoing HIV gene
expression, which again validates the importance of DNAPK during the reactivation of latent HIV provirus. These
findings reveal yet another way through which DNA-PK
contributes to HIV transcription.

DNA-PK facilitates RNAP II pause release by
phosphorylating and recruiting TRIM28 at LTR
DNA-PK has been shown to interact and catalyze the
TRIM28 phosphorylation at serine 824 residue, p-TRIM28(S824) [37, 39]. This modification converts TRIM28 from
a transcriptionally repressive factor to a transcriptionally
active factor [37–39]. It has been recently documented
that TRIM28 potently suppresses HIV-1 expression by
utilizing both SUMO E3 ligase activity and epigenetic
adaptor function [43]. We hypothesized that if DNA-PK
plays a major role in TRIM28 activation by catalyzing its
phosphorylation at serine 824, then DNA-PK inhibition or
depletion in cells should reduce TRIM28 phosphorylation
and thus contribute to the suppression of HIV gene
repression, observed upon ablation of DNA-PK. We
examined the effect of DNA-PK inhibitors on the TRIM28
phosphorylation at the serine 824 residue by western blot,
using an antibody that detects specifically p-TRIM28(S824). Jurkat cells were treated overnight with the DNAPK inhibitor NU7441; then cell media was replaced with
fresh media containing NU7441 along with TNF-α. After
30 minutes, nuclear-extracts were prepared and the levels of
TRIM28 and p-TRIM28-(S824) were assessed. The results
showed that DNA-PK inhibitor effectively reduced TNF-αinduced TRIM28-(S824) phosphorylation (Figure 8A and
8B). However, the total TRIM28 protein levels were almost
unaffected upon DNA-PK inhibition.
We further evaluated the impact of DNA-PK
knockdown on TRIM28 and p-TRIM28-(S824) in J3
clone of Jurkat cells. Following DNA-PK depletion, we
observed clear reduction in p-TRIM28-(S824) levels
(Figure 8C and 8D). Interestingly, we also noted some
reduction in the total TRIM28 levels. Overall data suggest
that DNA-PK-mediated activation (phosphorylation)
of TRIM28 may contribute to DNA-PK induced HIV
transcription by relieving paused RNAP II. To confirm this
notion, we next analyzed the recruitment of TRIM28 and
p-TRIM28-(S824) in the presence and absence (depletion)
of DNA-PK at HIV LTR. This analysis used the DNA-PK
knocked-down clone J3 and control (scrambled shRNA)
Jurkat cells carrying the latent HIV provirus, pHR’-PNLwildTat-d2GFP (Jurkat-HIV-GFP), in their genome. The
ChIP assays were performed before and after activating
the cells with TNF-α (10 ng/ml) for 30 minutes. The
immunoprecipitated DNA was analyzed using two primer
sets, one amplifying the promoter region of the LTR (–116
to +4 with respect to the transcription start site, Figure
9A) and another downstream Nuc-2 region of the LTR
(+286 to +390 with respect to the transcription start site,
www.oncotarget.com

DNA-PK inhibitors severely impair HIV-1
replication and transmission in MT-4 cells
The human T cell line MT-4 carrying Human T cell
Lymphotropic Virus-1 (HTLV-1) is highly susceptible
to HIV-1 infection and induced toxicity. We used these
cells to examine the ability of NU7026 and NU7441
inhibitors to suppress spreading of HIV-1 infection and
evaluate the cytotoxicity of these compounds. The cells
were pre-treated for 24 hours with various concentrations
of the two compounds (2, 4, 8, 16, 32 µM) or the highest
concentration of DMSO used to dilute the compounds as
control. The next day the cells were infected with ×4LAI.04,
washed two times in PBS and plated in 24-well plates
(for HIV infection) and 96-well plates (for MTT assay)
in medium containing the compounds. After 3 days, the
concentration of p24 was evaluated in the medium and
MTT assay was performed.
As shown in Figure 10A and 10B, both DNA-PK
inhibitors strongly inhibit HIV-1 replication compared
to the DMSO control. Moreover, NU7441, being a
highly specific inhibitor, inhibits HIV gene expression
more effectively at lower doses (Supplementary Figure
4C). The compounds were not cytotoxic even at highest
concentrations (Figure 10C and 10D).

DNA-PK inhibitor restricts the reactivation
of latent proviruses in peripheral blood
mononuclear cells (PBMCs) from HIV patients
Overall, the results documented so far confirm an
important role of DNA-PK in supporting HIV transcription
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and replication. We have shown that the small molecule
inhibitors of DNA-PK efficiently restrict HIV gene
expression, replication, and the reactivation of latent
proviruses in different cell types. To provide the clinical

relevance to these findings, we evaluated the ability of
DNA-PK inhibitors to restrict the reactivation of latent
HIV proviruses present in the PBMCs of HIV patients
on combination anti-retroviral treatment (cART). Ten

Figure 8: DNA-PK catalyzes the phosphorylation of TRIM28. Western blots were performed to evaluate the expression levels

of Trim28 and phospho-Trim28 [p-TRIM28 (S824)] in (A) Jurkat cells treated with increasing concentration of the DNA-PK inhibitor
NU7441 with or without TNF-α, and in (C) DNA-PK knockdown clone J3 and scrambled shRNA control. Densitometric analyses of
(B) Jurkat cells and (D) DNA-PK knockdown J3 clone were performed using ImageJ software. Data is expressed as mean ± SD; n = 3.
Significant differences in protein expression were evaluated; p < 0.05 (*), 0.01 (**), or 0.001 (***) against the respective controls.
www.oncotarget.com
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million PBMCs from 4 HIV-infected patients undergoing
successful cART treatment (undetectable viral load) were
mixed and used in each sample. The cells were treated

with either cART (2 NRTIs+1 PI, Zidovudine/Abacavir/
Fosamprenavir) alone, with DNA-PK inhibitor, NU7441
(12 µM) alone, or together with both NU7441+cART,

Figure 9: DNA-PK facilitates TRIM28 recruitment at HIV LTR. Recruitment kinetics of TRIM28 and p-TRIM28-(S824)
were assessed using ChIP assays in J3 and scrambled control, and also before and after reactivating latent HIV provirus. (A) Primer
set amplifying the promoter region of the LTR and (B) primers amplifying the downstream Nuc-2region of the LTR. Data represent the
percentages of the input after background subtraction. Results depicts the mean ± SD of two independent experiments and three separate
real-time qPCR measurements. Statistical significance, p < 0.05 (*) or 0.01 (**), marks the reactivation of latent HIV provirus in both wild
or reduced DNA-PK conditions.
www.oncotarget.com

714

Oncotarget

overnight. The next day, culture medium was replaced
with fresh medium containing cART and/or NU7441, and
the cells were stimulated with PMA/ionomycin/IL-2 for
3 days to reactivate latent HIV provirus. Cellular RNA
was isolated, cDNA was prepared and equal amounts of
cDNA (5 ng) were analyzed by qPCR, with a primer set
specific for the Nuc-2 region of LTR. The results were
normalized with GAPDH gene amplification as loading
control. We found that NU7441, with or without cART,
was able to restrict the reactivation of latent provirus,
which occurs following the stimulation with PMA/

ionomycin/IL-2. Notably, cART alone was not effective
in controlling latent proviral reactivation and HIV gene
expression (Figure 11A). Notably, NU7441 also restricted
the reactivation of latent provirus which was partially
reactivated while thawing the PBMCs (compare lanes 1
to 3 and 5). Viability of PBMCs was not compromised
by the treatments (Figure 11B). Instead, drug treatments,
by virtue of repressing HIV replication, enhanced
cell survival. This result validates our hypothesis that
transcriptional inhibitors, such as DNA-PK inhibitors, can
be used to suppress the ectopic reactivation of latent HIV

Figure 10: DNA-PK inhibitors completely block HIV replication in MT-4 T cells without showing cytotoxicity. MT-4 cells
were treated overnight with increasing concentrations of the DNA-PK inhibitors (A) NU7026 or (B) NU7441; DMSO was used as solvent
control. Next day, the cells were infected with a replication competent ×4 virus (HIVLAI.04). After 3 days of culture, cells supernatants were
evaluated for p24 with Luminex (Luminexcorp). Significant inhibition of HIV replication in presence of DNA-PK inhibitors (increasing
dose) were evaluated; p < 0.0001 (****). The cytotoxicity of the inhibitors in MT-4 cells was assessed with MTT assay. No cytotoxicity was
detected in cells treated with (C) NU7026 or (D) NU7441, compared to the DMSO control. All the results represent the mean ± SD of four
independent measurements.
www.oncotarget.com
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provirus, a main contributor to viral blips, even in HIV
patients undergoing successful cART.

[16] and present studies, we propose that DNA-PK
promotes the initiation phase of HIV transcription mainly
by directly catalyzing the phosphorylation of RNAP II
CTD at Ser5. DNA-PK also facilitates the elongation
phase of transcription by both directly catalyzing the
phosphorylation of Ser2 of CTD and recruiting P-TEFb
at LTR. We also found that DNA-PK, by phosphorylating
TRIM28 at the specific serine residue (S824), converts

DNA-PK promotes HIV transcription by
supporting different aspects of HIV transcription
In order to summarize our results, we present the
following model (Figure 12). Based on our previous

Figure 11: DNA-PK inhibitors restrict the reactivation of latent provirus in PBMCs of HIV-infected patients. PBMCs

from HIV-infected patients were treated with either ART alone, NU7441 alone or both together overnight. The day after, medium was
replaced with fresh medium containing the drugs and the cells were stimulated for 3 days with PMA/ionomycin/IL-2 to reactivate latent
HIV provirus present in PBMCs. (A) Cellular RNAs were isolated and evaluated via RT-qPCR. (B) Cell viability was examined by MTS
assays. The results were reproduced 3 more times, by mixing PBMCs of 4 different patients each time. Presented data are the mean ± SD
for four experiments. Statistical significance; p < 0.05 (*) or 0.001 (***) marks the restriction to reactivation of latent provirus in the presence
of DNA-PK inhibitor.
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it from an RNAP II pausing factor into an elongationsupporting factor. Thus, DNA-PK also augments HIV
transcription by relieving the RNAP II pausing. Altogether,
DNA-PK enhances the HIV transcription by supporting
the multiple phases of transcription, namely initiation,
RNAP II pause release, and elongation. Therefore, besides
controlling replication, DNA-PK inhibition may be used
to prevent the reactivation of the latent HIV proviruses.

P-TEFb recruitment at HIV LTR. Accordingly, we noted
that DNA-PK inhibition or depletion severely impairs
HIV transcription, replication, and reactivation of latent
provirus. Overall, these results reveal the underlying
molecular mechanisms through which DNA-PK facilitates
HIV gene expression and reactivation of latent provirus.
The most well-characterized activity of DNA-PK
is to repair the broken ends of DNA double strand breaks,
especially during non-homologous end joining (NHEJ)
DNA-repair pathway [26, 27, 69, 70]. DNA repair, although
essential for cell survival, may constitute a mechanism of
tumor resistance to certain DNA damaging agents used
in cancer treatment, such as radiation exposure [71].
Consequently, over-expression of DNA-PKcs is a common
occurrence in many human cancers [72]. Therefore,
the inhibition of DNA-PK is an attractive target for the
development of cancer therapies. Accordingly, DNA-PK
inhibitors are under trial in several preclinical and phase-I
clinical studies as anti-cancer agents [45, 56–59]. Although
very little is known about the cellular consequence of
DNA-PK, potential utility of DNA-PK inhibitors has been
proposed as valuable tumor therapeutics.
Notably, DNA-PK was originally discovered as part
of SP1 transcription complexes [73] and as a regulatory

DISCUSSION
Unraveling the molecular mechanisms that control
HIV life cycle, especially transcription, replication,
and reactivation of the latent provirus, is crucial for
cure and eradication of HIV. The studies presented
herein provide strong and compelling evidence for the
important role of DNA-PK in supporting various stages
of HIV transcription, which subsequently promote HIV
replication and reactivation from latency. We discovered
that DNA-PK promotes transcriptional initiation by
catalyzing the phosphorylation of CTD at Ser5; relieves
RNAP II pausing by phosphorylating TRIM28 at S824;
facilitates transcriptional elongation by both catalyzing
the phosphorylation of CTD at Ser2 and promoting of

Figure 12: DNA-PK facilitates HIV transcription by targeting multiple mechanisms. In our model presented here we suggest

that DNA-PK supports the initiation phase of transcription by catalyzing the phosphorylation of RNAP II CTD at Ser5. DNA-PK facilitates
transcriptional elongation by enhancing phosphorylation of RNAP II CTD at Ser2, both via directly catalyzing and through the recruitment
of P-TEFb at HIV LTR. DNA-PK relieves the RNAP II pausing by catalyzing the phosphorylation of TRIM28.
www.oncotarget.com
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component of transcriptionally poised RNA polymerase
II [74]. However, its role during transcription was studied
very superficially, and was limited to showing the
interaction of DNA-PK with RNAP II [16, 21, 44, 75].
To extend those observations, for the first time, we have
shown the importance of DNA-PK during transcription,
its presence at HIV LTR, and confirmed DNA-PK
as an integral part of the RNAP II holoenzyme [16].
Recently, our findings have been confirmed, and a similar
mechanism involving DNA-PK has been proposed for the
transcription of inducible cellular genes [38, 76, 77]. In
this investigation, we have demonstrated that DNA-PK
enhances HIV transcription by facilitating the various
stages of transcription. We also noted reduced nuclear
level of DNA-PK in unstimulated cells, which upregulates
upon cell stimulation (Figures 3, 5, and 9), suggesting a
clear role of reduced DNA-PK levels in supporting HIV
latency in quiescent cells.
The observation of enhanced recruitment of DNAPK at HIV LTR during HIV gene expression and the
synergistic recruitment kinetics of DNA-PK with RNAP
II along HIV genome prompted us to explore further the
role of DNA-PK during HIV transcription, replication,
and latent proviral reactivation. In this investigation we
utilized highly specific DNA-PK inhibitors that are known
to induce phenotypes similar to those seen in DNA-PK
deficient cell lines and DNA-PK knockout mice [45,
56]. The knockdown studies reaffirmed the specificity of
inhibitors towards DNA-PK. Analysis of the reactivation
of latent HIV provirus expressing luciferase reporter gene
under the control of HIV LTR promoter unequivocally
demonstrated that DNA-PK inhibitors are very strong
repressors of HIV transcription and replication (Figure
1), since TNF-α, a strong inducer of latent provirus, was
unable to increase HIV gene expression in the presence
of optimal concentrations of specific DNA-PK inhibitors.
The dose-dependent nature of this repression was also
confirmed in experiments with two different cell lines,
representing CD4+ lymphoid and myeloid cells, the major
targets of HIV infection in patients. The physiological
relevance of these results was established by confirming
the inhibitory effect of DNA-PK inhibitors in suppressing
the reactivation of latent HIV provirus in primary CD4+
T cells, infected either ex vivo (Figure 1) or obtained from
HIV patients (Figure 11). We noted some cytotoxicity
of DNA-PK inhibitors in primary CD4+ T cells at
concentrations over 16 µM; therefore, the inhibitors
were always used within physiologically non-toxic range
(Figure 1). Under these conditions, DNA-PK inhibitors
even supported the survival of primary cells isolated
from HIV patients (Figure 11) and also from the MT-4
cells (Figure 10). This observation confirms that DNAPK-mediated inhibition of HIV replication averts HIVmediated cytotoxicity.
In our prior study, we have confirmed the presence
of DNA-PK at HIV LTR and, by performing in vitro
www.oncotarget.com

kinase assays, demonstrated that DNA-PK was able to
catalyze RNAP II CTD phosphorylation in vitro, using
purified DNA-PK protein [16]. To extend those in vitro
findings, here we demonstrated that DNA-PK does, in
fact, phosphorylate RNAP II CTD in vivo. We have shown
that following the treatment of cells with either specific
DNA-PK inhibitor or upon DNA-PK depletion (Figures
3 and 4), RNAP II CTD phosphorylation (Ser2 and Ser5)
becomes highly impaired in both Jurkat and THP-1 cells.
Therefore, our results demonstrate that DNA-PK enhances
HIV transcription by promoting both the initiation and
elongation phases of HIV transcription.
The interaction between DNA-PK and P-TEFb
subunits has also been documented [62, 63]. These
findings impelled us to determine if DNA-PK also
increases the RNAP II CTD phosphorylation by bringing
P-TEFb along with it to HIV LTR. In fact, upon DNA-PK
depletion, in parallel to impaired DNA-PK recruitment,
we noted severely decreased recruitment of both P-TEFb
subunits at HIV LTR (Figure 5). Even after proviral
reactivation with TNF-α, we observed highly restricted
recruitment of P-TEFb; we also noted that DNA-PK
depletion impacted the levels of cellular Tat, the main
recruiter of P-TEFb at LTR (Figures 5 and 6C).
In DNA-PK knockdown cells, we discovered that
HIV expressing functionally impaired Tat (H13L), a
mutation prevalent in latent proviral isolates [8, 61, 64],
was almost ineffective in supporting HIV transcription.
Moreover, HIV carrying wild-type Tat was also highly
defective in expressing the reporter GFP gene (Figure
6A and 6B). The finding that DNA-PK depletion results
in reduced HIV protein expression, such as Tat (Figure
6C), was further supported by the impaired latent proviral
reactivation and replication in DNA-PK inhibited and
depleted cells (Figures 1, 2, and 3). Moreover, previously
we and others have revealed that Tat phosphorylation
catalyzed by DNA-PK is essential for its optimal
activity [16, 78]. Hence, besides Tat levels, the deficient
phosphorylation of Tat due to DNA-PK inhibition
or depletion may contribute to reduced Tat activity
and P-TEFb recruitment; this is a subject for future
investigations.
Given the fact that chromatin structure around the
promoter of a gene controls its expression, we investigated
which specific epigenetic changes induced by DNA-PK
promote HIV transcription, and the reversion of those
changes upon DNA-PK inhibition (Figure 7). Similar to
our prior findings, we observed greater recruitment of
DNA-PK at LTR upon reactivation of latent proviral. In
parallel to DNA-PK, we also noticed higher recruitment
of RNAP II and co-recruitment of other transcription
factors, such as NF-κB and P-TEFb at LTR, which clearly
indicates enhanced ongoing transcription from LTR.
Simultaneously, we found accumulation of euchromatic
marks, such as acetylation of core histones (H3-AC), but
removal of heterochromatic marks and enzymes involved,
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such as H3K27me3 and of HDAC3. All of these changes
facilitate the establishment of transcriptionally active
euchromatin structures at HIV LTR, which support HIV
transcription. However, upon inhibition of DNA-PK, the
whole process gets reversed, and we noted the loss of
euchromatic marks and accumulation of heterochromatic
marks at HIV LTR, which leads to the generation of
transcriptionally repressive heterochromatin structures
at HIV LTR. Heterochromatin structures suppress
transcription by impeding the access of transcription
machinery as confirmed by reduced levels of RNAP II and
other transcription factors at LTR.
Next, we investigated how DNA-PK promotes
HIV transcription by regulating TRIM28 activity
(Figure 10). Recently, TRIM28 was confirmed as one
of the factors that facilitate RNAP II pausing at several
cellular genes, including HIV [39, 42]. DNA-PK has
been shown to interact directly with TRIM28 and
catalyze the TRIM28 phosphorylation at serine 824
residue, p-TRIM28-(S824) [37, 39]. This modification
makes TRIM28 functionally active and converts it from
a transcriptionally pausing factor to a transcriptionally
active factor, which allows the release of paused
RNAP II and promotes transcriptional elongation [37,
39]. Thus, like SPT5 a component of another pausing
factor DSIF complex, TRIM28 first promotes RNAP
II pausing. However after phosphorylation at S824, it
becomes activator of transcription and facilitates the
release of paused RNAP II [39, 40]. We showed that
TRIM28 is indeed the substrate of DNA-PK, as specific
inhibition or depletion of DNA-PK resulted in reduced
phosphorylation of TRIM28 at S824. However, during this
study we noted that the P-TEFb inhibitor, 5,6-Dichloro1-beta-D- ribofuranosylbenzimidazole (DRB) does not
affect TRIM28 phosphorylation, suggesting that TRIM28
S824 phosphorylation is not mediated by P-TEFb (not
shown). The data suggest that reduced phosphorylation
of TRIM28, upon DNA-PK inhibition or depletion,
stabilizes the pausing state of RNAP II and contributes
to decreased HIV transcription. Subsequently, in ChIP
assays, in parallel to DNA-PK recruitment at LTR,
we found the enhanced recruitment of TRIM28 and
phosphorylated TRIM28 (S824) at HIV LTR. Specifically,
at the Nuc-2 region of LTR, we noticed relatively higher
fold enrichment of p-TRIM28 (S824) after stimulation
with TNF-α. The accumulation of p-TRIM28 (S824)
marks the presence of the transcription-supporting form
of TRIM28 and thus indicates the transformation of
paused RNAP II into a processive elongating RNAP II.
Following DNA-PK depletion, we found very limited
levels of p-TRIM28 (S824) at LTR, even after activation,
demonstrating that DNA-PK is the main kinase that
catalyzes the phosphorylation of TRIM28. However,
besides DNA-PK, ATM has also been shown to catalyze
the phosphorylation of TRIM28 at S824 [38, 79, 80]. It
should be noted that following DNA-PK knockdown, we
www.oncotarget.com

found reduced presence of both TRIM28 and p-TRIM28
(S824) at LTR, clearly suggesting a primary role of DNAPK in the recruitment of TRIM28 at HIV LTR. It appears
that ATM cannot compensate for the lack of this activity
of DNA-PK. The detailed investigation of this important
mechanism is a subject for future investigations utilizing
a combination of biochemical, genetic, and genomics
approaches.
We also evaluated the effect of the DNA-PK
inhibitors NU7026 and NU7441 on HIV-1 replication in
MT-4 cells, using a prototypical replication competent ×4
variant of HIV-1 (HIV-1 X4LAI.04). Both inhibitors were
able to completely inhibit HIV replication at low doses
(Figure 10A and 10B) and were well-tolerated by the cells
(Figure 10C and 10D).
Finally, we evaluated the clinical relevance of the
DNA-PK inhibitor NU7441 by assessing its impact in
restricting the reactivation of latent provirus in PBMCs
from HIV-infected patients (Figure 11). We found an
almost complete block of HIV gene expression in the
cells treated with NU7441, even after stimulation of
latently infected cells with α-CD3/CD28 antibodies.
Notably, HAART treatment, which is highly successful
in controlling HIV replication, was not effective in
controlling HIV gene expression of the reactivated latent
provirus. These results strongly argue for the inclusion
of transcriptional inhibitors, such as DNA-PK inhibitors,
as a supplement to HAART regimens for suppressing
transient reactivation of latent proviruses. While
continuous treatment with HAART prevents the infection
of neighboring cells, in sanctuary sites, including gutassociated lymphoid tissue (GALT) and central nervous
system (CNS), the transient episodes of viral activation
can lead to spread of viral reservoir and contribute to
immune activation.
Thus, our findings unraveled the molecular
mechanisms utilized by DNA-PK to enhance HIV
transcription and confirmed the physiological relevance
of DNA-PK inhibitors in restricting HIV gene expression,
replication, and reactivation of latent provirus. We
propose a model to depict these multiple activities of
DNA-PK (Figure 12). Briefly, our data suggest that
DNA-PK enhances HIV transcription by supporting
the initiation phase of transcription by catalyzing the
phosphorylation of RNAP II CTD at Ser5. By catalyzing
the phosphorylation of TRIM28, specifically at residue
S824, DNA-PK converts TRIM28 from a pausing factor
to an elongating factor, thus relieving RNAP II pausing.
Additionally, DNA-PK supports the elongation phase
of HIV transcription by enhancing the processivity of
RNAP II through augmenting the CTD phosphorylation
at Ser2, both directly and via facilitating the recruitment of
P-TEFb at HIV LTR. Consequently, by repressing all these
pathways, DNA-PK inhibitors show a profound effect on
HIV replication and latent proviral reactivation. Overall,
our results support the notion that supplementing cART
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regimens with DNA-PK inhibitors may, besides restricting
HIV replication and protein production, also target HIVassociated malignancies.

standard protocol [81]. The cell viability was regularly
evaluated by propidium iodide staining.

Luciferase assay

MATERIALS AND METHODS

THP-1-pHR’-P-Luc, Jurkat-pHR’-P-Luc and
primary CD4+ T cells were plated in 6-well plates
at a concentration 106 cells/ml, in complete RPMI
medium. The cells were pre-incubated with different
concentrations of DNA-PK inhibitors or with dimethyl
sulfoxide (DMSO) as control, overnight. Since the
inhibitors were dissolved in DMSO, a set of cells was
treated with the highest used concentration of DMSO
as negative/background control. Next day, cells were
supplied with fresh media containing inhibitors. The
latent HIV provirus in the Jurkat and THP-1 cell lines
was reactivated by treatment with Tumor Necrosis
Factor alpha (TNF-α, 10 ng/ml), whereas in primary
CD4+ T cells by stimulation through T cell receptor
(TCR) with α-CD3/CD28 antibodies-coated beads (25
μl/106 cells). After 48 hours, the cells were harvested
and washed three times with phosphate-buffered saline
(PBS). Subsequently, Bradford assays (Bio-Rad) were
performed and equal amount of cell extracts were used
in each luciferase reaction. Luciferase levels in the cells
were assessed using a Promega commercial kit (Cat#
E4530; Madison, WI, USA). Briefly, the cells were lysed
for 30 minutes at room temperature with passive lysis
buffer and centrifuged at 14000 rpm for 2 minutes. 5 µl
of samples were added to individual wells of a 96-well
plate, followed by 70 µl of luciferase substrate/assay
buffer. Samples were tested in triplicate. Luminescence
was read in a Microplate Luminometer (Bio-Rad or
Turner Biosystems).

Reagents
DNA-PK Inhibitors: NU7026 (Cat. # S2893)
and NU7441 (Cat. # S2638) from Selleckchem,
while IC86621 (Cat. # 404009-40-1) from SigmaAldrich, was purchased. Stock solutions were made
in DMSO at 5 mM concentration. DNA-PKcs shRNA
vectors (Cat # sc-35200-SH) were purchased from
Santa Cruz Biotech. In some experiments, we also
used the lentiviral vector pHR’Sin-Puro with shRNA,
which carry puromycin resistance gene and expresses
shRNA through H1 Pol-III promoter. The shRNAs to
DNA-PKcs (5′-GAACACTTGTACCAGTGTT-3′) or
(5′-GATCGCACCTTACTCTGTT-3′) and scrambled
control (5′-TTGATGCACTTACTAGATTAC-3′), were
cloned. A total of 4 to 6 μg of VSV-G pseudotyped
lentiviral vectors carrying specific or control shRNA were
used for knockdown.

Cell culture conditions
The latently infected cell lines, J1.1 and U1 were
obtained from AIDS Research and Reference Reagent
Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, U.S. National Institutes of
Health (NIH). The Jurkat, THP-1, U937, and MT-4 cell
lines were obtained from ATCC, Manassas, VA, USA.
However, primary T cells and PBMCs were isolated from
blood in our lab. All these cells were cultured in RPMI
medium with l-glutamine (Invitrogen), 10% fetal bovine
serum (FBS), penicillin (100 IU/ml), Ciprofloxacin (10
µM) and streptomycin (100 µg/ml). Primary cells were
also supplied with primocin (invivoGen), 25 mM HEPES
(pH 7.2) and IL-2 (20 U/ml of recombinant human IL-2
[R&D Systems, Inc. or Roche]). The cells were grown in
incubator maintaining CO2 at 5% and temperature at 37°C.

Cell cytotoxicity: MTS assay and MTT assay
The cytotoxicity of DNA-PK inhibitors in Jurkat,
THP-1 and primary CD4+ T cells carrying pHR’PLuc, was assessed using 3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) reagent (Promega) following the
supplier’s protocol. Briefly, the cells were seeded (3 × 103
cells/ well) in 96-well plates and incubated with increasing
concentrations of NU7441 or NU7026 for 5 days. Then
the cells were incubated for 4 hours with the MTS reagent
directly added in the culture wells. Subsequently, the
optical density was measured at 490 nm, using a visible
light 96-well plate reader.
The cytotoxicity of DNA-PK inhibitors in MT-4
cells was evaluated with 3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide (MTT) reagent (SigmaAldrich). The cells were pre-treated for 24 hours with the
DNA-PK inhibitors NU7026 and NU7441 at different
concentrations and DMSO as control, and seeded (2 × 104
cells/well) in 96-well plate in 100 µl of RPMI 10% FBS.

Cell lines and viruses
THP-1, Jurkat and primary cells were infected with
replication-incompetent HIV (pHR’P-Luc, pHR’-PNLwildTat-d2GFP or pHR’-PNL-H13LTat-d2GFP), carrying
reporter genes either luciferase or GFP under the control
of the HIV LTR promoter. VSV-G-pseudotyped HIV
particles were packaged as previously described. The
latently infected promonocytic U1 and T-lymphocytic J1.1
cell line harbor integrated replication-competent latent
provirus and constitutively express very low amounts
of HIV proteins. The primary cells were infected with
replication-competent HIV-1 NL4-3 and ×4LAI.04 using
www.oncotarget.com
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Reverse transcriptase-(RT)-qPCR

The day after the cells were infected with ×4LAI.04, they
were washed two times in PBS and plated again in a 96well plate. After 3 days, the MT-4 were incubated for 2
hours at 37°C with MTT reagent, then treated with 100 µl
of DMSO per well for 30 minutes and the optical density
was measured at 570 nm in a plate reader.

Total RNA was isolated from cells using a High
Pure RNA Isolation Kit (Roche) or Trizol (ThermoFisher).
The mRNA was reverse transcribed into complementary
DNA (cDNA) using OneTaq RT-PCR Kit (New England
Biolabs) or oligo dT primer. cDNA was quantified via
Real-time quantitative PCR (RT-qPCR), which was
performed in CFX96 Real-time PCR detection system
(Bio-Rad) using SYBR green reaction mix (Bio-Rad).
The data were normalized to the corresponding values for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The Nuc-2 primer sequences are described in the ChIP
section.

HIV replication assay
U1, J1.1, and CD4+T cells were pre-treated overnight
with multiple concentrations of DNA-PK inhibitors,
prior to stimulation with 10 ng/ml of TNF-α for 56 hours
more. HIV replication was determined by the reverse
transcriptase (RT) assay as previously described in [82].
Briefly, the cell supernatants were incubated overnight at
37°C with RT buffer (1 mM DTT, 5 mM MgCl2, 50 mM
Tris-HCL, 20 mM of KCl, poly A, poly (dT), 0.1% Triton
and [3H] TTP). The samples were then spotted on DEAE
Filter mat paper and washed with 5% disodium phosphate
(Na2HPO4) and water. The samples were dried completely,
and the activity was read in a Betaplate counter (Wallac,
Gaithersburg, MA, USA).
For replication assay in MT-4 cells, the cells were pretreated for 24 hours with the DNA-PK inhibitors NU7026 or
NU7441 at different concentrations and DMSO as control,
and seeded (105 cells/well) in 24 well plate in 1 ml of RPMI
10% FBS. Next day, the cells were infected with 10 µL of
viral stock ×4LAI.04 (0.7-ng/mL p24gag antigen) with ×4LAI.04
and culture medium was replaced with fresh RPMI with
DNA-PK inhibitors. Thus, inhibitors were present during
the entire culture period. After 3 days, HIV-1 replication in
MT-4 was evaluated by measuring the levels of p24gag in
cell culture medium using a dynamic immunofluorescent
cytometric bead assay (Luminex).

Chromatin immunoprecipitation (ChIP) assays
and q-PCR
ChIP assays were performed using a previously
described protocol [8, 60]. For cell stimulation, we either
used 10 ng/ml TNF-α (for cell lines) or 25 μl per 106 cells
of α-CD3/CD28 antibodies bound Dynal beads along with
20 U/ml of IL-2 (for primary T cells). The chromatin was
immunoprecipitated using different antibodies, detailed in
the antibodies section. Each sample (5%) was analyzed
by quantitative real-time PCR (qPCR) to assess the
amount of sample immunoprecipitated by an individual
antibody. Control preimmune IgG value was subtracted
from each sample value to remove the background counts.
SYBR green PCR master mix (12.5 μl/sample; Bio-Rad)
combined with 1 μl of each primer, 5 μl of ChIPed DNA
and water to a final volume 25 μl was analyzed by q-PCR.
The primers used were the following (numbered with
respect to the transcription start site): Promoter region of
HIV-1 LTR (promoter) forward,–116, AGC TTG CTA CAA
GGG ACT TTC C and reverse +4, ACC CAG TAC AGG
CAA AAA GCA G; Nucleosome-1 region HIV-1 LTR (Nuc1) forward +30, CTG GGA GCT CTC TGG CTA ACT A
and reverse +134, TTA CCA GAG TCA CAC AAC AGA
CG; Nucleosome-2 region HIV-1 LTR (Nuc-2) forward
+283F, GACTGGTGAGTACGCCAAAAAT and reverse
+390R, TTTCCCATCGCGATCTAATTC glyceraldehyde
3-phosphate dehydrogenase (GAPDH) promoter forward,
–125, CAC GTA GCT CAG GCC TCA AGA C and reverse,
–10, AGG CTG CGG GCT CAA TTT ATA G; GAPDH was
also assessed by forward, –145, TAC TAG CGG TTT TAC
GGG CG and reverse, +21 TCG AAC AGG AGG AGC
AGA GAG CGA.

Western blot
Jurkat, and U937 cells (wild-type or DNA-PK
knockdown) were plated at 5 × 106/ml in Petri dishes.
The wild-type cells were incubated with 8 µM, 12 µM
and 16 µM of NU7441 overnight. Cells were lysed
with 0.5% NP-40 (supplemented with 10 mM HEPESKOH pH 7.9, 60 mM KCL, 1 mM EDTA, 1 mM DTT,
1 mM phenylmethylsulfonylfluoride (PMSF), 10 μg/mL
leupeptin, 10 μg/mL aprotinin. The isolated nuclei were
then lysed in a buffer comprising 250 mM Tris pH7.8,
60 mM KCL, 1 mM EDTA, 1 mM DTT, 1 mM PMSF,
10 μg/mL leupeptin, 10 μg/mL aprotinin, 100 mM NaF,
and 200 µM sodium orthovanadate with three freeze-thaw
cycles. Protein samples were separated by electrophoresis
in SDS-PAGE, transferred to a nitrocellulose membrane
and detected with specific antibodies. The immunoreactive
proteins, after incubation with appropriately labeled
secondary antibodies, were detected with an enhanced
chemiluminescence detection kit. Densitometric analysis
was done with ImageJ software.
www.oncotarget.com

Antibodies
The following antibodies where used in this study:
RNAP II (17-672, Millipore; 61667, Active Motif; or
sc-899, Santa Cruz), p-RNAP II (Ser2) (13499, Cell
Signaling; 3E10, Active Motif, ab5095, Abcam), p-RNAP
II (Ser5) (61085, Active Motif; 13523, Cell Signaling),
721

Oncotarget

H3-Ac (Upstate 07-593), H3K27me3 (07-449; Upstate),
DNA-PKcs (Sc-9051, Santa Cruz), p-DNA-PKcs (S2056)
(ab18192, Abcam), TRIM28 (A300-274A, Bethyl),
p-TRIM28 (S824) (A300-767A, Bethyl), Tat (ab6539,
Abcam), Cyclin T1 (sc-8128, Santa Cruz), p65 (sc-372
and sc-514451 Santa Cruz), CDK9 (sc-13130, sc-484),
CDK7 (A300-405A, Bethyl), HDAC1 (sc-7872 and sc6298, Santa Cruz), HDAC3 (sc-11417 and sc-376957
Santa Cruz), β-Actin (sc-47778 Santa Cruz).

even control the rate of HIV-associated cancers, as DNAPK inhibitors are under trial for cancer therapy.
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Flow cytometric analysis
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48 to 72 hours, the expression of the fluorescent reporter,
GFP, was assessed through fluorescence-activated cell
sorting (FACS) using a FACSCalibur flow cytometer. Data
were analyzed using Flowjo software.
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Statistical analysis
Data were analyzed using Microsoft Excel or
GraphPad Prism and ImageJ softwares. For paired samples,
statistical analyses were performed using Student’s t test.
Statistical comparisons between the control and tested
groups were analyzed using the one-way ANOVA. The p
value of statistical significance was set at either; p < 0.05
(*), 0.01 (**), 0.001 (***), or 0.0001 (****). All experiments
were independently repeated at least three times.

CONCLUSIONS
Overall, our results reveal the important role of
DNA-PK in supporting HIV transcription, replication,
and latent proviral reactivation. By performing luciferase
and reverse transcriptase assays, we demonstrated that
the restriction of DNA-PK activity via specific inhibitors
strongly represses HIV transcription and viral replication,
and confirmed these results not only in lymphoid and
myeloid cell lines, but also in primary CD4+ T cells.
Subsequently, by chromatin immunoprecipitation assays
we showed that specific DNA-PK inhibitors repress HIV
transcription by inducing transcriptionally repressive
chromatin structures at HIV LTR, and they inhibit both
the initiation and elongation phases of HIV transcription
by severely restricting the phosphorylation of the carboxyl
terminal domain (CTD) of RNAP II.
Given that the transcriptional block plays a major
role in sustaining HIV proviruses in the latent state,
this study sheds light on an important pathway that
regulates HIV latency. Moreover, these results support a
potential therapeutic use of specific DNA-PK inhibitors
as supplements in HAART/cART regimens to further
enhance the effectiveness of anti-HIV therapy and might
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